[A trial of applying an oily suspension of bleomycin endolymphatically in patients with Hodgkin's disease of the extraperitoneal lymph nodes].
This study summarized results of treatment of the extraperitoneal lymphatic nodes in patients with Hodgkin's disease with infusion of oily form of bleomycin into the lymphatic vessels. Sixty patients aged 17-69 yr. (mean 43 yr.), 24 women and 36 men with Hodgkin's disease staged IIIA-IVB after 6 cycles of chemotherapy with MOPP or MOPP/ABVD were investigated. Three months after the last cycles of chemotherapy neoplastic changes in the extraperitoneal lymphatic nodes were found in 18 patients only. These patients were treated with bleomycin injected within 30 min. in a daily dose of 30 mg up to total dose 60 mg. Total remission was found in 7 patients, in 4 patients the nodes were shrunken and in the remaining 7 patients there was no visible sings of the disease. Serum level of bleomycin was the highest a few minutes after injection (217-680 ng/ml) and was followed rapid decrease. The obtained results have led to the following conclusions: 1. Oily suspension of bleomycin is a method of chose in the treatment of patients with Hodgkin's disease with changes in the extraperitoneal node. 2. High dose of bleomycin applied directly to the lymphatic vessels leads to total or subtotal remission of the nodal changes. 3. The highest serum concentration of bleomycin was found after the injection. 4. The method in painless and safe the patients, fever may occur for a few hours only.
Ziółko
E
E
V Katedry i Kliniki Chorób Wewnetrznych Slaskiej Akademii Medycznej w Katowicach.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001761:Bleomycin / Q000008:administration & dosage*; D010478:Chemotherapy, Cancer, Regional Perfusion; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007272:Injections, Intralymphatic; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D012074:Remission Induction; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D000964:Antimetabolites, Antineoplastic; D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D011241:Prednisone